ArticleOncology letters2025
Immune infiltration and stromal heterogeneity in pancreatic cancer: A prognostic model guiding immunotherapy response.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic adenocarcinoma (PAAD) is among the most common malignant tumors of the gastrointestinal tract and has a poor prognosis. Research on its pathogenesis and treatment remains insufficient; therefore, the present study aimed to develop a novel model for predicting PAAD prognosis. Transcriptome data for pancreatic cancer were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases (GSE28735), with TCGA data serving as the training set and GSE28735 data as the validation set. Differential expression analysis of GSE28735 data was performed using the limma package, followed by the identification of potential prognostic genes through univariate Cox regression and least absolute shrinkage and selection operator regression. Patients were stratified into high- and low-risk groups based on risk scores, followed by survival analysis, nomogram construction, immune infiltration analysis and mutation analysis. Reverse transcription-quantitative PCR (RT-qPCR) experiments were performed for validation. A prognostic prediction model for PAAD was constructed using TCGA patient samples and comprised 12 genes. Kaplan-Meier analysis indicated that the model effectively distinguished between high- and low-risk groups, which corresponded with poor and favorable prognoses, respectively. Receiver operating characteristic curve analysis demonstrated high predictive accuracy. Additionally, significant differences in immune infiltration and mutation levels were observed between the two risk groups. RT-qPCR results further demonstrated that the expression of prognostic genes differed significantly between pancreatic cancer (PANC-1) and normal (HPDE-6) cell lines. In conclusion, the prognostic model developed in the present study may contribute to an improved understanding of PAAD prognosis and provide new tools for predicting prognosis and immune response in patients with PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.